1. Scrip
  2. >>Business

Astellas Stakes Claim In CAR-Ts For Solid Tumors With Poseida Deal

 
• By Alaric DeArment

Astellas is building off an existing relationship with the biotech formed last August, joining the growing number of large pharmas looking at tackling solid tumors with cell therapy.

• Source: Shutterstock

As a growing number of cell therapy developers expand their reach from hematological malignancies and into solid tumors, Japan-based drug maker Astellas Pharma, Inc. is staking its claim in a new deal with Poseida Therapeutics, Inc. to develop off-the-shelf CAR-T cell therapies for tougher-to-treat cancers.

Poseida and Astellas announced 1 May a deal in which Astellas subsidiary Xyphos will work with Poseida to develop two convertibleCAR-based allogeneic CAR-T cell therapy programs using Xyphos's ACCEL platform and Poseida's own CAR-T platform

Key Takeaways

  • Astellas announced a deal with Poseida to develop off-the-shelf CAR-T cell therapies for solid tumors.

  • The deal, worth potentially up to $600m for Poseida, builds on a financial relationship that the two companies established in August 2023

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

In Brief: Sanofi Commits $20bn To US R&D And Manufacturing By 2030

 
• By Sushmita Panda

Move by French major aligns with broader industry efforts to localize production amid political pressure, as Trump pushes to onshore manufacturing and hints at easing tariff threats.

Eisai Forecasts 73% Leqembi Sales Rise In FY25 As Demand Expands

 
• By Mandy Jackson

Eisai spent most of its FY24 earnings call discussing plans for growing sales of Biogen-partnered Alzheimer’s drug Leqembi from JPY44.3bn ($304.1m) to JPY76.5bn ($525.1m) in FY25.